Enalapril accelerates remodeling of the renal interstitium after release of unilateral ureteral obstruction in rats.
Complete ureteral obstruction in rats rapidly leads to renal interstitial expansion and fibrosis and this process is ameliorated by concomitant angiotensin converting enzyme inhibition (ACEI). However, models of intervention initiated after unilateral ureteral obstruction (UUO) release may be more analogous to human obstructive renal disease where treatment could more reasonably follow the discovery of obstructive uropathy as compared to models where treatment is initiated at the time of experimentally induced obstruction. We studied interstitial changes in rats before and after release of UUO and examined the effect of ACEI with 200mg/L of enalapril (E) in the drinking water on these changes. Rats were sacrificed after 10 (n=10) and 20 (n=10) days (D) of UUO or 10D after release of 10D of UUO (n=18). Eleven rats received E for 10D after UUO release. Cortical interstitial volume fraction [Vv(I/C)] measured by point counting was increased at 10D (0.32 +/- 0.05) and 20D (0.41 +/- 0.05) of UUO compared to contralateral and sham-operated kidneys (both 0.05 +/- 0.01, ANOVA, p <0.001). Vv(I/C) 10D after release from 10D of UUO (0.26 +/- 0.04) was lower than that of 10D of UUO (p<0.05) and much lower than those with 20D of UUO (p<0.001). However, rats treated with E from the time of UUO release had lower Vv(I/C) (0.21 +/- 0.07) than UUO released E untreated rats (p<0.05). Release of UUO initiates regression of interstitial expansion in rats. ACEI with enalapril significantly accelerates reversal of interstitial expansion after UUO release. This could have important implications for treatment of obstructive nephropathy in humans.
Koo
Ja Wook
JW
Department of Pediatrics, Sanggye Paik Hospital, Inje University, Seoul, Korea.
Kim
Youngki
Y
Rozen
Silvia
S
Mauer
Michael
M
D000704:Analysis of Variance; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D004195:Disease Models, Animal; D004656:Enalapril / Q000494:pharmacology*; D005355:Fibrosis / Q000188:drug therapy / Q000473:pathology; D007677:Kidney Function Tests; D008297:Male; D009400:Nephrosclerosis / Q000188:drug therapy* / Q000209:etiology; D011336:Probability; D051381:Rats; D011917:Rats, Inbred Lew; D012016:Reference Values; D012038:Regeneration / Q000187:drug effects; D012680:Sensitivity and Specificity; D014517:Ureteral Obstruction / Q000150:complications*
D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril